Does Illinois Medicaid Cover Wegovy or Zepbound?
Illinois (IL) GLP-1 access depends on three state-specific policy questions before it ever gets to pricing: does Illinois Medicaid cover weight-loss GLP-1s, has Illinois expanded Medicaid under the ACA, and does the state employee health plan cover them. Answering those first tells you whether you're likely working with insurance or planning for cash-pay.
Illinois Medicaid GLP-1 coverage: what the state's own documents say
Illinois Medicaid rules exclude 'Anorectic drugs' (89 Ill. Adm. Code 140.441) and the HFS preferred drug list effective July 27, 2026 lists GLP-1 drugs only under antidiabetics, with no entry for Wegovy, Zepbound, Saxenda or Foundayo; no HFS document names these drugs as non-covered, so this rests on the rule and their absence from the list.
Checked September 20, 2026 against: ilga.gov, hfs.illinois.gov.
Illinois state employee health plan: what the plan's own documents say
By statute (5 ILCS 375/6.11c, effective July 1, 2024) every Illinois state employee plan must cover medically necessary injectable medication to improve glucose or weight loss for adults with prediabetes, gestational diabetes or obesity, but future coverage is denied unless the member enrolls and stays in the plan's lifestyle management program (the CVS Weight Management Program for the OAP/PPO-type plans); as described, the mandate covers injectables, so oral Wegovy and Foundayo are not covered by it.
Checked September 20, 2026 against: cms.illinois.gov, cms.illinois.gov.
Notable insurers active in Illinois (not independently verified): Blue Cross Blue Shield of Illinois, Aetna, UnitedHealthcare.
Why GLP-1 coverage varies this much by state
Medicaid is a state-federal partnership, not a single national program. Each state Medicaid agency sets its own preferred drug list (PDL) and prior-authorization criteria within federal minimum requirements. Weight-loss drugs are not a federally mandated Medicaid benefit, so states choose independently whether to cover them - which is why only 10 of 50 states currently do (Illinois is not one of them).
State employee health plans are a useful bellwether. These plans cover hundreds of thousands of state workers and negotiate directly with pharmacy benefit managers, so their coverage decisions often signal where commercial insurers in that state are heading. North Carolina's State Health Plan, for example, ended coverage of weight-loss GLP-1s on April 1, 2024, after its board voted 4-3 to cut it citing the drugs' high cost - a case that other states and large employers have watched closely.
Medicaid expansion status shapes who even has coverage to begin with. States that haven't adopted ACA Medicaid expansion have narrower Medicaid eligibility overall, which - combined with the weight-loss GLP-1 exclusion most states apply regardless of expansion status - pushes a larger share of residents in those states toward commercial insurance, telehealth, or manufacturer self-pay as their only realistic path.
National reference pricing (same nationwide - your actual cost depends on your plan)
These prices are the same across all 50 states because manufacturer list prices, self-pay programs, and telehealth pricing don't vary by state - only insurance coverage and copay do, which is why the Illinois-specific policy facts above matter more than the table below for predicting your actual cost.
| Drug | Covered by insurance | Manufacturer self-pay | Telehealth | Cash retail |
|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $1,349 |
| Ozempic 11.6% weight loss | $63 | - | $399 | $1,028 |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 | $449 | $1,349 |
| Zepbound 22.5% weight loss | $88 | $299 | $499 | $1,059 |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $1,069 |
| Saxenda 8.4% weight loss | $63 | - | $399 | $1,349 |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 | - | $1,099 |
| CagriSema 20.4% weight loss | $88 | $599 | - | $1,499 |
Cheapest cash-pay GLP-1 paths for Illinois residents
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $249 cheapest | $1,349 | Get →ad |
| Ozempic 11.6% weight loss | $63 | - | $399 | $199 cheapest | $1,028 | Get →ad |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 cheapest | $449 | - | $1,349 | Get →ad |
| Zepbound 22.5% weight loss | $88 | $299 cheapest | $499 | $299 cheapest | $1,059 | Get →ad |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $299 cheapest | $1,069 | Get →ad |
| Saxenda 8.4% weight loss | $63 | - | $399 cheapest | - | $1,349 | Get →ad |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 cheapest | - | - | $1,099 | Get →ad |
Illinois carrier coverage details
National carriers active in Illinois (this list is not independently verified). Drill into each carrier's prior-auth requirements, formulary, and appeal playbook.
Frequently asked questions
Does Illinois Medicaid cover Wegovy or Zepbound for weight loss?
No. Illinois Medicaid rules exclude 'Anorectic drugs' (89 Ill. Adm. Code 140.441) and the HFS preferred drug list effective July 27, 2026 lists GLP-1 drugs only under antidiabetics, with no entry for Wegovy, Zepbound, Saxenda or Foundayo; no HFS document names these drugs as non-covered, so this rests on the rule and their absence from the list. This was checked against Illinois's own documents on September 20, 2026; coverage rules change often, so confirm with your plan before relying on it. Coverage for type 2 diabetes (Ozempic, Mounjaro) is a separate question. Medicare's GLP-1 Bridge, which started July 1, 2026, works separately from Medicaid and applies in every state.
Has Illinois expanded Medicaid under the ACA?
Yes - Illinois has adopted Medicaid expansion, which broadens who qualifies for Medicaid coverage generally, though it does not by itself guarantee GLP-1 weight-loss coverage (see above).
Does the Illinois state employee health plan cover Wegovy or Zepbound?
Partly. By statute (5 ILCS 375/6.11c, effective July 1, 2024) every Illinois state employee plan must cover medically necessary injectable medication to improve glucose or weight loss for adults with prediabetes, gestational diabetes or obesity, but future coverage is denied unless the member enrolls and stays in the plan's lifestyle management program (the CVS Weight Management Program for the OAP/PPO-type plans); as described, the mandate covers injectables, so oral Wegovy and Foundayo are not covered by it. This was checked against Illinois's own plan documents on September 20, 2026; plan terms are reset each plan year, so confirm with your plan before relying on it.